> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Amgen BLA for Migraine Therapy
- URL: https://www.fdaweb.com/amgen-bla-for-migraine-therapy/
- Published: 2017-05-18T12:00:00.000Z
- Updated: 2026-09-14T22:24:36.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5138726

Amgen has submitted a BLA for erenumab to prevent migraine. The human monoclonal antibody works by blocking the Calcitonin Gene-Related Peptide receptor. according to the company. The submission includes data from pivotal studies in patients with episodic and chronic migraine, it says.

  
“The erenumab global clinical trial program has enrolled more than 2,600 patients experiencing four or more migraine days per month, with some patients receiving erenumab for up to three years,” Amgen says. “Results from the chronic migraine study were published in *The Lancet Neurology* in April 2017 and detailed results from Phase 3 in episodic migraine have been submitted for publication.”